Ardelyx, Inc. (ARDX): Price and Financial Metrics


Ardelyx, Inc. (ARDX): $1.84

0.07 (+3.95%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ARDX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ARDX POWR Grades

  • Growth is the dimension where ARDX ranks best; there it ranks ahead of 96.63% of US stocks.
  • The strongest trend for ARDX is in Growth, which has been heading up over the past 179 days.
  • ARDX's current lowest rank is in the Stability metric (where it is better than 3.44% of US stocks).

ARDX Stock Summary

  • With a price/sales ratio of 25.39, ARDELYX INC has a higher such ratio than 94.76% of stocks in our set.
  • With a year-over-year growth in debt of -43.22%, ARDELYX INC's debt growth rate surpasses merely 6.63% of about US stocks.
  • Revenue growth over the past 12 months for ARDELYX INC comes in at -17.17%, a number that bests merely 9.45% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to ARDELYX INC, a group of peers worth examining would be MRIN, TTNP, WISA, EMKR, and AAOI.
  • Visit ARDX's SEC page to see the company's official filings. To visit the company's web site, go to www.ardelyx.com.

ARDX Valuation Summary

  • In comparison to the median Healthcare stock, ARDX's price/sales ratio is 862.89% higher, now standing at 46.7.
  • ARDX's EV/EBIT ratio has moved up 30.7 over the prior 102 months.

Below are key valuation metrics over time for ARDX.

Stock Date P/S P/B P/E EV/EBIT
ARDX 2022-11-01 46.7 4.6 -1.8 -1.7
ARDX 2022-10-31 44.6 4.4 -1.7 -1.7
ARDX 2022-10-28 43.1 4.2 -1.7 -1.6
ARDX 2022-10-27 41.1 4.0 -1.6 -1.5
ARDX 2022-10-26 41.7 4.1 -1.6 -1.5
ARDX 2022-10-25 40.5 4.0 -1.6 -1.5

ARDX Growth Metrics

    Its 2 year net income to common stockholders growth rate is now at -67.91%.
  • Its 3 year net income to common stockholders growth rate is now at -52.44%.
  • Its 2 year cash and equivalents growth rate is now at -55.54%.
Over the past 15 months, ARDX's revenue has gone down $3,408,000.

The table below shows ARDX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 9.009 -123.797 -114.136
2022-06-30 5.196 -132.959 -134.83
2022-03-31 3.983 -135.954 -153.081
2021-12-31 10.097 -152.551 -158.165
2021-09-30 10.877 -130.672 -150.807
2021-06-30 12.417 -115.96 -125.328

ARDX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ARDX has a Quality Grade of C, ranking ahead of 26.73% of graded US stocks.
  • ARDX's asset turnover comes in at 0.061 -- ranking 306th of 682 Pharmaceutical Products stocks.
  • XBIO, CBAY, and BPTH are the stocks whose asset turnover ratios are most correlated with ARDX.

The table below shows ARDX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.061 0.919 -0.887
2021-03-31 0.063 0.912 -0.724
2020-12-31 0.036 0.981 -0.618
2020-09-30 0.035 0.982 -0.579
2020-06-30 0.040 0.911 -0.719
2020-03-31 0.035 0.908 -0.806

ARDX Price Target

For more insight on analysts targets of ARDX, see our ARDX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.21 Average Broker Recommendation 1.62 (Moderate Buy)

ARDX Stock Price Chart Interactive Chart >

Price chart for ARDX

ARDX Price/Volume Stats

Current price $1.84 52-week high $2.19
Prev. close $1.77 52-week low $0.49
Day low $1.73 Volume 6,831,900
Day high $1.94 Avg. volume 4,497,110
50-day MA $1.42 Dividend yield N/A
200-day MA $0.98 Market Cap 344.93M

Ardelyx, Inc. (ARDX) Company Bio


Ardelyx is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative, minimally-systemic, small molecule therapeutics that work exclusively in the gastrointestinal tract to treat cardio-renal, gastrointestinal and metabolic diseases. The company was founded in 2007 and is based in Fremont, California.


ARDX Latest News Stream


Event/Time News Detail
Loading, please wait...

ARDX Latest Social Stream


Loading social stream, please wait...

View Full ARDX Social Stream

Latest ARDX News From Around the Web

Below are the latest news stories about ARDELYX INC that investors may wish to consider to help them evaluate ARDX as an investment opportunity.

Ardelyx to Present at the 34th Annual Piper Sandler Healthcare Conference

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that management will participate in a fireside discussion at the 34th Annual Piper Sandler Healthcare Conference on Thursday, December 1, 2022, at 10:00 a.m. ET in New York City.

Yahoo | November 22, 2022

2 Biotech Stocks That Can Rocket Higher in 2023, According to Wall Street

If your answer's yes, the biotech industry has you covered. Last week, two biotech companies independently announced some surprisingly good news that got the attention of investment banks on Wall Street. Ardelyx (NASDAQ: ARDX) is a commercial-stage biotech that markets a drug called Ibsrela for irritable bowel syndrome.

Yahoo | November 20, 2022

Ardelyx (ARDX) Up 41% After FDA Committee Endorses CKD Drug

The FDA's CRDAC recommends granting marketing approval to Ardelyx's (ARDX) oral pill to control serum phosphorus in adult patients with chronic kidney disease on dialysis.

Yahoo | November 18, 2022

Analyst Sees This Kidney Disease Company's Stock Could Rise Sixfold, But Lists Two Issues

Piper Sandler raised its price target on Ardelyx Inc (NASDAQ: ARDX) to $8 from $3 and upgraded to Overweight from a Neutral rating. The upgrade follows a surprisingly positive advisory committee vote of 9-4 in favor of tenapanor as monotherapy and 10-2 (1 abstention) as combo therapy for controlling serum phosphorus in dialysis-dependent chronic kidney disease (CKD). While we found the vote itself remarkable, it was more meaningful that the vote was not split along “party lines,” the analyst wro

Yahoo | November 18, 2022

Fed Comments Continue To Weigh On Stocks Midday

Stocks are firmly lower midday, as bond yields rise following hawkish comments from St. Louis Federal Reserve President James Bullard.

TalkMarkets.com | November 17, 2022

Read More 'ARDX' Stories Here

ARDX Price Returns

1-mo 33.33%
3-mo 82.18%
6-mo N/A
1-year 106.16%
3-year 4.10%
5-year 23.70%
YTD 67.27%
2021 -31.99%
2020 -13.79%
2019 319.28%
2018 -72.88%
2017 -53.52%

Continue Researching ARDX

Here are a few links from around the web to help you further your research on Ardelyx Inc's stock as an investment opportunity:

Ardelyx Inc (ARDX) Stock Price | Nasdaq
Ardelyx Inc (ARDX) Stock Quote, History and News - Yahoo Finance
Ardelyx Inc (ARDX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8151 seconds.